320
Participants
Start Date
July 1, 2022
Primary Completion Date
December 31, 2025
Study Completion Date
June 30, 2026
Buprenorphine/Naloxone
Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
Treatment as usual
Participants will receive a referral to buprenorphine treatment in the community
RECRUITING
Division of Parole & Probation, Baltimore
Lead Sponsor
Friends Research Institute, Inc.
OTHER